Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
Active, not recruiting · NCT04220021 · Registry updated 2026-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD | Frontotemporal Lobar Degeneration, Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, psychiatric disorder, spinal cord disorder | Active, not recruiting | Phase 2 | 2026-08-20 | NCT04220021 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ALS Association | 8 |
| United States Department of Defense | 319 |
| University of Florida | 315 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UF Health at the University of Florida | Gainesville | United States | 5 |